Less Ads, More Data, More Tools Register for FREE

Pin to quick picksTime Finance Regulatory News (TIME)

Share Price Information for Time Finance (TIME)

Share Price is delayed by 15 minutes
Get Live Data
46.00    0.75 (1.66%)
Bid:
45.00
Ask:
47.00
Spread: 2.00 (4.444%)
Market Cap: £42.17m
TIME Live PriceLast checked at - London Stock Exchange

Intraday Time Finance Share Chart

New Technology

18 Sep 2006 08:46

Timestrip PLC18 September 2006 TIMESTRIP PLC ("Timestrip" or the "Company") Technology Breakthrough Timestrip develops new label technology for vaccines Timestrip Plc, which develops and markets unique label technologies, is delighted to announce that it has developed a label that is capable of recordingwhether temperature sensitive products have been accidentally frozen during transport or storage. The iStripTM is a patent pending label which undergoes an irreversible colour change when exposed to freezing temperatures. Developed in response to demand from the pharmaceutical industry, iStripTM is designed to be mass-produced at low cost and to be fully integrated into the packaging of products such as vaccines, protein based pharmaceuticals, foodstuffs and fertilizer. Accidental freezing of Diptheria, Tetanus, Pertussis and Hepatitis B vaccines, and combination vaccines, can compromise their immunological potency. Recent studies in the UK, USA, Canada, Pakistan, Malaysia, Hungary, Mongolia and other countries have found widespread freezing at many levels of the vaccine distribution system. The high incidence of this problem and the resulting health risks have made the monitoring and elimination of accidental freezing a priority for organizations such as WHO, UNICEF and PATH (Program for AppropriateTechnology in Health). Paul Freedman, Joint CEO of Timestrip Plc, commented: "Current indicators cost up to $3.50 per item and can only be used at case or pallet level - iStripTM will be marketed at a fraction of this cost, making it acost effective option at an individual product level. We believe that the cost-benefit attractions of the technology make it a potential candidate for adoption as a stipulated feature on vaccines. We are currently in discussions with manufacturers, distributors and global health organizations and are targeting initial revenues towards the end of 2007." Enquiries: Paul Freedman/Reuben Isbitsky, Joint CEOs, Timestrip plc 01462 440 700Shane Dolan, Biddicks 020 7448 1000Fergus Marcroft, Evolution Securities 020 7071 4300 This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
15th Nov 202312:54 pmRNSChange of Nominated Adviser & Corporate Broker
9th Nov 20237:00 amRNSTrading Update
7th Nov 202311:45 amRNSResult of AGM
23rd Oct 20238:30 amRNSDirector Share Purchase
19th Oct 20237:00 amRNSDirector Share Purchase
11th Oct 20237:00 amRNSDirector Share Purchases
3rd Oct 20237:00 amRNSDirector/PDMR Shareholdings: Vesting of Options
27th Sep 20238:30 amRNSNotice of AGM
26th Sep 20237:00 amRNSQ1 Trading Update
26th Sep 20237:00 amRNSFinal Results
19th Sep 20237:00 amRNSAppointment of Independent Non-Executive Directors
12th Sep 20237:00 amRNSOwn-Book Update, Notice of Results, Pres & AGM
11th Jul 20237:00 amRNSDirector Share Purchase
29th Jun 20237:00 amRNSFull Year Trading Update
24th May 20239:04 amRNSDelivery of First Asset-Based Lending Facility
3rd May 20237:00 amRNSTrading Update & Notice of Final Results
8th Mar 20237:00 amRNSQ3 Trading Update: Pre-Tax Profits up 172%
9th Feb 202311:40 amRNSHolding in Company
26th Jan 202311:05 amRNSSecond Price Monitoring Extn
26th Jan 202311:00 amRNSPrice Monitoring Extension
26th Jan 20237:00 amRNSInterim Results
20th Dec 20221:24 pmRNSExercise of Options & Director/PDMR Shareholding
16th Dec 20227:00 amRNSH1 Trading Update & Notice of Interim Results
14th Nov 20227:00 amRNSDirector Share Purchases
3rd Nov 20227:00 amRNSMelloLondon Investor Conference
31st Oct 20222:00 pmRNSResult of AGM
19th Oct 20227:00 amRNSOwn Book Lending Portfolio reaches record £145m
5th Oct 20227:00 amRNSDirector Share Purchase
4th Oct 202212:00 pmRNSDirector/PDMR Shareholding
23rd Sep 20222:15 pmRNSNotice of AGM
22nd Sep 20227:00 amRNSQ1 Trading Update
22nd Sep 20227:00 amRNSFinal Results for the year ended 31 May 2022
15th Sep 20227:00 amRNSNotice of Results & Q1 Update and Presentation
6th Sep 20227:00 amRNSAppointments Strengthen Asset Finance Division
22nd Jul 20227:00 amRNSNew LTIP & Director/PDMR Shareholding
19th Jul 20227:02 amRNSDirector Share Purchases
18th Jul 20227:00 amRNSDirector Share Purchase
7th Jul 20227:00 amRNSTrading Update & Notice of Final Results
10th Jun 20227:00 amRNSNotice of Trading Update and Investor Presentation
5th May 20229:19 amRNSHolding in Company
27th Apr 20223:28 pmRNSHolding in Company
27th Apr 202212:51 pmRNSHolding in Company
26th Apr 20223:30 pmRNSTR-1 Holding in Company
26th Apr 20229:36 amRNSTR-1 Holding in Company
14th Feb 202210:00 amRNSExercise of Options & Director/PDMR Shareholdings
20th Jan 20227:00 amRNSInterim Results
5th Jan 20227:00 amRNSNotice of Interim Results Investor Presentation
15th Dec 20217:00 amRNSH1 Trading Update & Notice of Interim Results
21st Oct 20213:40 pmRNSResult of AGM & Directorate Change
1st Oct 20217:00 amRNSVesting of Share Options

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.